This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
Genetic signature of liver cancer cell response to zebularine to predict therapeutic response	<p><i>In vitro</i> and mouse studies identified a gene signature response to zebularine that could help predict therapeutic outcomes in liver cancer. In hepatocellular carcinoma (HCC) cell lines, a gene expression signature of response to the DNA methylation inhibitor zebularine distinguished between drug-sensitive and drug-resistant cell lines with accuracies of 70%–95%. A 20-gene signature of zebularine response stratified HCC patients based on overall survival ($p < 0.002$) and disease recurrence ($p < 0.0009$). Next steps could include determining if the signature predicts response to epigenetic-targeted therapies.</p> <p>SciBX 3(43); doi:10.1038/scibx.2010.1310 Published online Nov. 4, 2010</p>	Patent and licensing status unavailable	<p>Andersen, J.B. <i>et al. Sci. Transl. Med.</i>; published online Oct. 20, 2010; doi:10.1126/scitranslmed.3001338</p> <p>Contact: Snorri S. Thorgeirsson, National Cancer Institute, Bethesda, Md. e-mail: snorri_thorgeirsson@nih.gov</p>